Caplacizumab-yhdp

Class: Antithrombotic Agents, Miscellaneous
Chemical Name: Immunoglobulin, anti-(human von Willebrand's blood-coagulation factor VIII domain A1) (human-Lama glama dimeric heavy chain fragment PMP12A2h1)
Molecular Formula: C₁₂₁₃H₁₈₉₁N₃₅₇O₃₈₀S₁₀
CAS Number: 915810-67-2
Brands: Cablivi

Medically reviewed by Drugs.com on Feb 8, 2022. Written by ASHP.

Introduction

Caplacizumab-yhdp is an antithrombotic agent.

Uses for Caplacizumab-yhdp

Caplacizumab-yhdp has the following uses:

Caplacizumab-yhdp is a von Willebrand factor-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Caplacizumab-yhdp Dosage and Administration

General

Caplacizumab-yhdp is available in the following dosage form(s) and strength(s):

For injection: 11 mg as a lyophilized powder in a single-dose vial.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

• The first dose should be administered by a healthcare provider as a bolus intravenous injection. Administer subsequent doses subcutaneously in the abdomen.

• Caplacizumab-yhdp should be administered upon the initiation of plasma exchange therapy. The recommended dose of caplacizumab-yhdp is as follows:

• First day of treatment: 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.

• Subsequent treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.

• Treatment after the plasma exchange period: 11 mg subcutaneous injection once daily for 30 days beyond the last plasma exchange.

• If after initial treatment course, sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.

• Discontinue caplacizumab-yhdp if the patient experiences more than 2 recurrences of aTTP while on caplacizumab-yhdp.

Cautions for Caplacizumab-yhdp

Contraindications

Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients.

Warnings/Precautions

Bleeding

Caplacizumab-yhdp incr...